 Catherine Derington
Concepts (152)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antihypertensive Agents | 31 | 2026 | 511 | 6.970 |
Why?
| | Hypertension | 32 | 2026 | 1264 | 6.290 |
Why?
| | Blood Pressure | 24 | 2026 | 1769 | 2.600 |
Why?
| | Angiotensin Receptor Antagonists | 7 | 2026 | 114 | 1.990 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 6 | 2026 | 222 | 1.920 |
Why?
| | Veterans | 9 | 2026 | 1603 | 1.160 |
Why?
| | Adrenergic beta-Antagonists | 4 | 2026 | 250 | 1.130 |
Why?
| | Dementia | 4 | 2025 | 304 | 1.080 |
Why?
| | Cardiovascular Diseases | 10 | 2026 | 2171 | 1.020 |
Why?
| | Atherosclerosis | 4 | 2023 | 409 | 0.940 |
Why?
| | Liraglutide | 1 | 2025 | 32 | 0.920 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2025 | 41 | 0.900 |
Why?
| | Primary Prevention | 3 | 2025 | 220 | 0.890 |
Why?
| | Authorship | 1 | 2025 | 49 | 0.850 |
Why?
| | Glucagon-Like Peptides | 1 | 2025 | 70 | 0.830 |
Why?
| | Cognitive Dysfunction | 3 | 2025 | 464 | 0.820 |
Why?
| | Aged | 35 | 2026 | 25947 | 0.810 |
Why?
| | Publishing | 1 | 2025 | 114 | 0.800 |
Why?
| | Recombinant Fusion Proteins | 1 | 2025 | 675 | 0.750 |
Why?
| | Empathy | 1 | 2025 | 182 | 0.750 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2024 | 439 | 0.720 |
Why?
| | Hypoglycemic Agents | 3 | 2025 | 1389 | 0.690 |
Why?
| | Losartan | 1 | 2020 | 13 | 0.660 |
Why?
| | Lisinopril | 1 | 2020 | 15 | 0.660 |
Why?
| | Nutrition Surveys | 7 | 2023 | 282 | 0.660 |
Why?
| | Angioedema | 1 | 2020 | 15 | 0.650 |
Why?
| | Hypercholesterolemia | 1 | 2021 | 93 | 0.630 |
Why?
| | Naloxone | 1 | 2020 | 132 | 0.600 |
Why?
| | Medication Adherence | 7 | 2026 | 539 | 0.580 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 201 | 0.560 |
Why?
| | United States | 21 | 2026 | 15988 | 0.550 |
Why?
| | Middle Aged | 25 | 2026 | 35928 | 0.510 |
Why?
| | Atrial Fibrillation | 1 | 2023 | 550 | 0.510 |
Why?
| | Humans | 54 | 2026 | 144957 | 0.500 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2025 | 2584 | 0.490 |
Why?
| | Heart Diseases | 1 | 2020 | 350 | 0.490 |
Why?
| | Male | 34 | 2026 | 72406 | 0.480 |
Why?
| | Drug Overdose | 1 | 2020 | 370 | 0.470 |
Why?
| | Female | 34 | 2026 | 78376 | 0.460 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2021 | 988 | 0.430 |
Why?
| | Insulin Glargine | 2 | 2025 | 88 | 0.430 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 543 | 0.420 |
Why?
| | Stroke | 1 | 2023 | 1258 | 0.410 |
Why?
| | Cross-Sectional Studies | 11 | 2026 | 5872 | 0.380 |
Why?
| | Cost-Benefit Analysis | 4 | 2023 | 636 | 0.340 |
Why?
| | Risk Factors | 10 | 2026 | 10792 | 0.320 |
Why?
| | Anticholesteremic Agents | 2 | 2022 | 154 | 0.320 |
Why?
| | Healthcare Disparities | 3 | 2026 | 728 | 0.310 |
Why?
| | Drug Therapy, Combination | 5 | 2026 | 1048 | 0.310 |
Why?
| | Adult | 17 | 2026 | 40506 | 0.290 |
Why?
| | Retrospective Studies | 9 | 2026 | 17101 | 0.290 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2026 | 68 | 0.280 |
Why?
| | Drug Combinations | 4 | 2023 | 392 | 0.270 |
Why?
| | Drug Costs | 2 | 2026 | 116 | 0.260 |
Why?
| | United States Department of Veterans Affairs | 3 | 2026 | 768 | 0.240 |
Why?
| | Practice Patterns, Physicians' | 2 | 2026 | 1358 | 0.240 |
Why?
| | Follow-Up Studies | 5 | 2022 | 5417 | 0.240 |
Why?
| | Rural Health | 1 | 2026 | 87 | 0.230 |
Why?
| | Stroke Volume | 2 | 2026 | 651 | 0.230 |
Why?
| | Cholesterol, LDL | 3 | 2024 | 358 | 0.230 |
Why?
| | Eicosapentaenoic Acid | 2 | 2023 | 36 | 0.230 |
Why?
| | Drug Resistance | 1 | 2026 | 153 | 0.230 |
Why?
| | Sodium | 1 | 2026 | 197 | 0.220 |
Why?
| | Ezetimibe | 2 | 2022 | 24 | 0.220 |
Why?
| | Aged, 80 and over | 6 | 2026 | 8279 | 0.220 |
Why?
| | Grief | 1 | 2025 | 47 | 0.220 |
Why?
| | Comparative Effectiveness Research | 1 | 2025 | 170 | 0.210 |
Why?
| | Health Expenditures | 1 | 2026 | 194 | 0.210 |
Why?
| | Databases, Factual | 2 | 2020 | 1486 | 0.210 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2025 | 146 | 0.210 |
Why?
| | Myocardial Infarction | 2 | 2022 | 1209 | 0.210 |
Why?
| | Risk Reduction Behavior | 1 | 2026 | 226 | 0.200 |
Why?
| | Time-to-Treatment | 1 | 2026 | 245 | 0.200 |
Why?
| | Proportional Hazards Models | 3 | 2022 | 1325 | 0.200 |
Why?
| | Pharmacies | 1 | 2024 | 42 | 0.200 |
Why?
| | Pharmacy | 1 | 2024 | 33 | 0.200 |
Why?
| | Health Care Costs | 2 | 2024 | 427 | 0.200 |
Why?
| | Text Messaging | 1 | 2026 | 182 | 0.190 |
Why?
| | Gastrointestinal Diseases | 1 | 2025 | 216 | 0.190 |
Why?
| | Thiazides | 1 | 2022 | 1 | 0.190 |
Why?
| | Drug Monitoring | 1 | 2026 | 395 | 0.180 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 2022 | 8 | 0.180 |
Why?
| | Warfarin | 1 | 2023 | 170 | 0.180 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2022 | 25 | 0.180 |
Why?
| | Calcium Channel Blockers | 1 | 2022 | 165 | 0.180 |
Why?
| | Heart Failure | 2 | 2026 | 2323 | 0.180 |
Why?
| | Rural Population | 1 | 2026 | 650 | 0.170 |
Why?
| | Hyperlipidemias | 1 | 2022 | 122 | 0.170 |
Why?
| | Proprotein Convertase 9 | 1 | 2021 | 87 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2024 | 301 | 0.160 |
Why?
| | Health Behavior | 1 | 2026 | 786 | 0.160 |
Why?
| | Cardiology | 1 | 2023 | 353 | 0.150 |
Why?
| | Data Mining | 1 | 2020 | 117 | 0.150 |
Why?
| | Hospitalization | 2 | 2021 | 2434 | 0.150 |
Why?
| | Frailty | 1 | 2023 | 198 | 0.150 |
Why?
| | Angina, Stable | 1 | 2019 | 18 | 0.150 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 220 | 0.150 |
Why?
| | Propensity Score | 1 | 2021 | 367 | 0.150 |
Why?
| | Drug Administration Schedule | 1 | 2020 | 783 | 0.140 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 257 | 0.140 |
Why?
| | Risk Assessment | 2 | 2025 | 3676 | 0.140 |
Why?
| | Coronary Angiography | 1 | 2020 | 323 | 0.140 |
Why?
| | Anticoagulants | 1 | 2023 | 724 | 0.140 |
Why?
| | Goals | 1 | 2019 | 184 | 0.130 |
Why?
| | Treatment Outcome | 5 | 2026 | 11695 | 0.130 |
Why?
| | Veterans Health | 1 | 2019 | 189 | 0.130 |
Why?
| | Patient Selection | 1 | 2021 | 719 | 0.130 |
Why?
| | Exercise Test | 1 | 2020 | 634 | 0.130 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1721 | 0.120 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2020 | 2032 | 0.120 |
Why?
| | Survival Rate | 1 | 2021 | 2092 | 0.120 |
Why?
| | Decision Support Systems, Clinical | 1 | 2020 | 265 | 0.120 |
Why?
| | Sex Characteristics | 1 | 2021 | 791 | 0.120 |
Why?
| | Electronic Health Records | 2 | 2020 | 1177 | 0.110 |
Why?
| | Cohort Studies | 2 | 2023 | 5965 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2021 | 741 | 0.110 |
Why?
| | Time Factors | 2 | 2026 | 7183 | 0.100 |
Why?
| | Biomarkers | 2 | 2026 | 4275 | 0.100 |
Why?
| | Patient Care Team | 1 | 2019 | 689 | 0.100 |
Why?
| | Health Personnel | 1 | 2020 | 748 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2021 | 3608 | 0.100 |
Why?
| | Patient Acceptance of Health Care | 1 | 2019 | 886 | 0.090 |
Why?
| | Algorithms | 1 | 2020 | 1839 | 0.090 |
Why?
| | Prevalence | 3 | 2023 | 2836 | 0.090 |
Why?
| | Primary Health Care | 1 | 2020 | 1734 | 0.070 |
Why?
| | Incidence | 2 | 2026 | 2883 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2024 | 1563 | 0.060 |
Why?
| | Mississippi | 1 | 2026 | 29 | 0.060 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2026 | 133 | 0.060 |
Why?
| | Adolescent | 2 | 2026 | 22453 | 0.050 |
Why?
| | California | 1 | 2026 | 475 | 0.050 |
Why?
| | American Heart Association | 1 | 2026 | 350 | 0.050 |
Why?
| | Medicare Part D | 1 | 2024 | 23 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2026 | 405 | 0.050 |
Why?
| | Health Literacy | 1 | 2026 | 184 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2023 | 121 | 0.050 |
Why?
| | Renin-Angiotensin System | 1 | 2023 | 78 | 0.050 |
Why?
| | Drug Prescriptions | 1 | 2024 | 285 | 0.050 |
Why?
| | Metformin | 1 | 2025 | 319 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 2020 | 166 | 0.040 |
Why?
| | Self Report | 1 | 2024 | 873 | 0.040 |
Why?
| | Health Status Disparities | 1 | 2022 | 321 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2026 | 1099 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2023 | 768 | 0.030 |
Why?
| | Medicare | 1 | 2023 | 887 | 0.030 |
Why?
| | Young Adult | 2 | 2026 | 14126 | 0.030 |
Why?
| | Telemedicine | 1 | 2026 | 948 | 0.030 |
Why?
| | Registries | 1 | 2024 | 2385 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1269 | 0.030 |
Why?
| | Pandemics | 1 | 2023 | 1695 | 0.030 |
Why?
| | Aging | 1 | 2024 | 1966 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2925 | 0.020 |
Why?
|
|
Derington's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|